University of Colorado Cancer Center
D

Intrapatient Subpopulation Heterogeneity and the Potential Ramifications in Multiple Myeloma

By University of Colorado Cancer Center FEATURING Daniel Sherbenou
By University of Colorado Cancer Center FEATURING Daniel Sherbenou
20 views
June 23, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Recommended

21:05

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

3.4K views
17:52

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.2K views
21:20

Spine Ablation in 2023: Indications, Goals, Guidelines, Evidence, an…

Jason Levy

3.6K views
16:42

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

1.6K views
24:35

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

616 views
35:27

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

632 views
26:59

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

136 views
28:20

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

681 views
15:35

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

368 views
17:46

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies on a …

Insights from 2023 ASH Annual Meeting

A. Jakubowiak

1.4K views
24:23

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

619 views
15:00

New

FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

Dana-Farber Cancer Institute

P. Richardson

280 views
20:23

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

401 views
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

884 views
09:51

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

466 views
19:08

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Insights from 2023 ASH Annual Meeting

R. Banerjee

870 views
13:15

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?"

2024 ASCO® Annual Meeting Insights Hub

O. Landgren

414 views
36:10

Highlights in Plasma Cell Disorders From ASCO® and EHA

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

466 views
13:47

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

2024 ASCO® Annual Meeting Insights Hub

B. Derman

395 views
22:33

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Integrity CE

S. Usmani, J. Hillengass

208 views
AUTOPLAY